Patient Convenience Study
Launched by BOEHRINGER INGELHEIM · Nov 4, 2015
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- Cohort A:
- • 1. A. Written informed consent prior to participation
- • 2. A. Female and male patients \>= 18 years of age with a diagnosis of non-valvular atrial fibrillation.
- • 3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.
- • 4. A. Patients switched to Pradaxa® according Summary of Product Characteristics and physician's discretion.
- • OR
- Cohort B:
- • 1. B. Written informed consent prior to participation.
- • 2. B. Female and male patients \>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment).
- • 3. B. Stroke prevention treatment initiated with Pradaxa® or VKA according to Summary of Product Characteristics and physician's discretion.
- Exclusion criteria:
- • 1. Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC).
- • 2. Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in atrial fibrillation.
- • 3. Current participation in any clinical trial of a drug or device.
- • 4. Current participation in an European registry on the use of oral anticoagulation in AF.
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Braine L'alleud, , Belgium
Brussels, , Belgium
Brussel, , Belgium
Bruxelles, , Belgium
De Pinte, , Belgium
Dendermonde, , Belgium
Diest, , Belgium
Edegem, , Belgium
Leuven, , Belgium
Lier, , Belgium
Maaseik, , Belgium
Meise, , Belgium
Mol, , Belgium
Mol, , Belgium
Mons, , Belgium
Nijlen, , Belgium
Ottignies Louvain La Neuve, , Belgium
Roeselare, , Belgium
Tienen, , Belgium
Frederikssund, , Denmark
Herning, , Denmark
Hjørring, , Denmark
Hvidovre, , Denmark
Nykøbing F, , Denmark
Næstved, , Denmark
Roskilde, , Denmark
Svendborg, , Denmark
Agrinio, , Greece
Alexandroupoli, , Greece
Arta, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Chalkidiki, , Greece
Chania, , Greece
Drama, , Greece
Giannitsa, , Greece
Glyfada, Athens, , Greece
Hrakleion ,Crete, , Greece
Ierapetra, Crete, , Greece
Ioannina, , Greece
Ioannina, , Greece
Ioannina, , Greece
Kalamata, , Greece
Karditsa, , Greece
Katerini, , Greece
Kavala, , Greece
Kerkyra, , Greece
Komotini, , Greece
Larissa, , Greece
Patra, , Greece
Patra, , Greece
Serres, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Trikala, , Greece
Tripoli, , Greece
Veroia, , Greece
Volos, , Greece
Xanthi, , Greece
Xilokastro, , Greece
Amsterdam, , Netherlands
Beugen, , Netherlands
Capelle A/D Ijssel, , Netherlands
Den Haag, , Netherlands
Ede, , Netherlands
Goes, , Netherlands
Groningen, , Netherlands
Heerenveen, , Netherlands
Heerlen, , Netherlands
Nijmegen, , Netherlands
Schiedam, , Netherlands
Uden, , Netherlands
Veldhoven, , Netherlands
Bergen, , Norway
Førde, , Norway
Lierskogen, , Norway
Nesbru, , Norway
Oslo, , Norway
Oslo, , Norway
Stavanger, , Norway
Svelvik, , Norway
Amadora, , Portugal
Angra Do Heroísmo, , Portugal
Aveiro, , Portugal
Braga, , Portugal
Guimarães, , Portugal
Horta, , Portugal
Matosinhos, , Portugal
Penafiel, , Portugal
Viana Do Castelo, , Portugal
Vila Franca De Xira, , Portugal
Bandhagen, , Sweden
Broby, , Sweden
Göteborg, , Sweden
Göteborg, , Sweden
Göteborg, , Sweden
Hässleholm, , Sweden
Kristianstad, , Sweden
Malmö, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Värnamo, , Sweden
Västerås, , Sweden
Patients applied
Trial Officials
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials